InsiderTrades

Form 4 for KNSA Kiniksa Pharmaceuticals International, plc

Accepted 2025-08-06 00:00:00 ET · period of report 2025-07-15 · accession 0001415889-25-021177 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-08-06 2025-07-15 KNSA Megna Michael R CAO A - Grant $15.63 +495 33.0K +2% +$7,737
D 2025-08-06 2025-08-04 KNSA Megna Michael R CAO M - OptEx $15.52 +17.0K 50.0K +51% +$263.8K
D 2025-08-06 2025-08-04 KNSA Megna Michael R CAO S - Sale+OE $32.35 -17.0K 33.0K -34% -$550.0K
D 2025-08-06 2025-08-04 KNSA Megna Michael R CAO M - OptEx $0.00 -17.0K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Ordinary Share 2025-07-15 A A 495 $15.63 33,041 D — —
2 Common Class A Ordinary Share 2025-08-04 M A 17,000 $15.52 50,041 D — —
3 Common Class A Ordinary Share 2025-08-04 S D 17,000 $32.35 33,041 D — — (F3) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.01 and $32.895. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
4 Derivative Share Option 2025-08-04 M D 17,000 $0.00 0 D $15.52 · — to 2030-03-12 17,000 Class A Ordinary Share (F4) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is March 13, 2020.